GALMED PHARMACEUTICALS WKN: A1XFUX ISIN: IL0011313900 Kürzel: GPH Forum: Aktien Thema: Hauptdiskussion

Du brauchst mehr Geduld!

... und vermutlich auch den Realtime-Kurs: https://www.marketwatch.com/investing/stock/glmd?mod=search_symbol

Oder hier: https://www.marketwatch.com/investing/stock/glmd?mod=search_symbol

Schon frustrierend wie schnell das wieder bei null war....

Gute news und die Aktie geht weiter gegen Süden. Muss man nicht verstehen.

brauch 1,52 für plus...

... gewesen ...

Drüber 😊

wir müssen über 1,42$

😊

1,30$ is the key

abwarten…..

Das klingt so gut aber steigt nicht nachhaltig sondern fällt gleich wieder. Wie schade. War kurz um plus...

The top-line results from the study showed that the 3-drugs' synergistic effect has the potential as a new fixed-dose combination treatment, enhancing the effect of Bayer's top selling cancer drug, Stivarga® (regorafenib); such combination could potentially become a life-cycle IP strategy when Stivarga's® main European and U.S. patents expires in August 2028 and July 2032, respectively. New patent applications (US 63/786,370 and US 63/915,832) have been submitted to USPTO. Metformin is typically the first-choice treatment for managing type 2 diabetes and is widely available in generic forms. The combination of Aramchol and Stivarga® is expected to enter phase 1b clinical trials early 2026 in metastatic colorectal cancer (CRC), hepatocellular (HCC) and cholangiocarcinoma patients with a planned expansion cohort including metformin.

🥁